Roth Capital Maintains Buy On Bluebird Bio Shares, Sees 29% Upside


In a research report released Thursday, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on bluebird bio Inc (NASDAQ:BLUE) with a price target of $50, which represents a potential upside of 29% from where the stock is currently trading.

Chattopadhyay said, “The goal of gene therapy is to provide a safe passage for transfusion dependent patients to freedom from transfusion. Because it is a highly individualized therapy, outcomes are likely to differ between patients. The ASH abstracts released earlier this morning highlighted just such an event, and with full data in about a month we caution investors that rapid transfusion independence may not be a realistic outcome.”

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of -13.8% and a 30.8% success rate. Chattopadhyay has a 6.9% average return when recommending BLUE, and is ranked #3327 out of 3363 analysts.